Alterity Therapeutics Files 6-K, Incorporates Cash Flow Report
Ticker: PRNAF · Form: 6-K · Filed: Apr 30, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, cash-flow, registration-statement
TL;DR
Alterity Therapeutics files 6-K with cash flow update, part of ongoing SEC filings.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on April 30, 2025, incorporating by reference its Quarterly Activities/Appendix 4C Cash Flow Report. This filing is part of ongoing registration statements on Form S-8 and Form F-3, indicating continued efforts in securities offerings and compliance.
Why It Matters
This filing provides an update on Alterity Therapeutics' financial activities and operational status, which is crucial for investors to assess the company's financial health and ongoing development efforts.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that incorporates other reports, not announcing new material events or financial distress.
Key Players & Entities
- ALTERITY THERAPEUTICS LTD (company) — Registrant
- PRANA BIOTECHNOLOGY LTD (company) — Former Company Name
- April 2025 (date) — Reporting Period
- 20250430 (date) — Filing Date
- Form S-8 (document) — Incorporated by reference into Registration Statement
- Form F-3 (document) — Incorporated by reference into Registration Statement
- 99.1 Quarterly Activities/Appendix 4C Cash Flow Report (document) — Exhibit submitted
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report information as required by Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically incorporating by reference the Quarterly Activities/Appendix 4C Cash Flow Report for the month of April 2025.
Which registration statements is this Form 6-K being incorporated into?
This Form 6-K is being incorporated by reference into Alterity Therapeutics' Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is the former name of Alterity Therapeutics Ltd?
The former name of Alterity Therapeutics Ltd was PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
What is the principal executive office address of Alterity Therapeutics?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
What specific report is being submitted as an exhibit with this 6-K?
Exhibit 99.1, the Quarterly Activities/Appendix 4C Cash Flow Report, is submitted with this 6-K.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 30, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).